Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04733963 | Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | unknown | Phase 2 | 112 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT04866862 | Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer | unknown | Phase 2 | 32 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER |
| 1 |
| Jul 25, 2022 |
| clinicaltrials |
| NCT05468177 | Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer(CIFOXRC) | unknown | Phase 2 | 66 | Tongji HospitalOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05451719 | Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy | unknown | Phase 2 | 116 | Fudan UniversityOTHER | 0 | Jul 12, 2022 | clinicaltrials |
| NCT05447715 | Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer | unknown | Phase 2 | 134 | Weijian GuoOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05426811 | Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients | unknown | Phase 1 / Phase 2 | 50 | China Medical University, ChinaOTHER | 0 | Jun 29, 2022 | clinicaltrials |
| NCT05438108 | SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC | unknown | Phase 2 | 30 | Huazhong University of Science and TechnologyOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT03668431 | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | unknown | Phase 2 | 25 | Massachusetts General HospitalOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT02588781 | Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study | unknown | Phase 2 | 23 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03947775 | HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL | unknown | Phase 2 | 228 | University Health Network, TorontoOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT05409417 | Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | unknown | Phase 2 / Phase 3 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05406206 | Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy | unknown | Phase 2 | 27 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05402124 | The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study | unknown | Phase 2 | 100 | University of CalgaryOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05371197 | Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer | unknown | Phase 2 | 26 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05353582 | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | unknown | Phase 2 | 168 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05354817 | Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin(Re-Play) | unknown | Phase 2 | 25 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05333809 | Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 20, 2022 | clinicaltrials |
| NCT05335460 | To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer | unknown | Phase 2 | 36 | Fujian Cancer HospitalOTHER_GOV | 0 | Apr 19, 2022 | clinicaltrials |
| NCT03940131 | Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR(REPAN) | unknown | Phase 2 | 30 | King Abdullah Medical CityOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03957733 | Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients. | unknown | Phase 2 / Phase 3 | 338 | King Abdullah Medical CityOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03457896 | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | unknown | Phase 2 | 35 | NSABP Foundation IncNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05292417 | Radiotherapy in Combination With Sintilimab,GM-CSF and Fruquintinib in Patients With MSS mCRC | unknown | Phase 2 | 71 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05299411 | Intravenous Iron Infusion on Chemotherapy-induced Anemia | unknown | Phase 2 | 80 | Korea University Guro HospitalOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT05289726 | Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105 | unknown | Phase 2 | 152 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT05266820 | Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer | unknown | Phase 2 | 120 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04970914 | Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003(ALTER-C003) | unknown | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04167436 | Fit for Surgery. Multimodal Prehabilitation in Colorectal Cancer Patients | unknown | Phase 2 / Phase 3 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04247256 | A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI | unknown | Phase 1 / Phase 2 | 35 | Scandion Oncology A/SINDUSTRY | 3 | Mar 2, 2022 | clinicaltrials |
| NCT03748680 | IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer(IMPROVE-IT) | unknown | Phase 2 | 64 | Karen-Lise Garm SpindlerOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT04911517 | Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC. | unknown | Phase 2 | 50 | Beijing Friendship HospitalOTHER | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04845490 | Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy(WUHIPEC02) | unknown | Phase 2 | 201 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Feb 21, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05241574 | Planned Non-operative Management for Rectal Cancer | unknown | Phase 2 | 23 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT05202236 | A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy | unknown | Phase 2 | 20 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05200299 | mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer | unknown | Phase 2 | 100 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05193292 | Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer | unknown | Phase 2 | 77 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05160727 | Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer | unknown | Phase 2 | 44 | Zhejiang Cancer HospitalOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT05130021 | A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer | unknown | Phase 2 | 130 | Maxinovel Pty., Ltd.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT04764006 | Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study | unknown | Phase 2 | 10 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04296019 | Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer | unknown | Phase 2 | 110 | Shanghai Zhongshan HospitalOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT04582981 | Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT05077839 | Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC(TOBACO) | unknown | Phase 2 | 184 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05068206 | A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | unknown | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02826837 | LEAC-102 for Advanced Colorectal Cancer | unknown | Phase 1 / Phase 2 | 30 | Taiwan Leader Biotech Corp.INDUSTRY | 0 | Oct 6, 2021 | clinicaltrials |
| NCT02948348 | Study to Nivolumab Following Preoperative Chemoradiotherapy | unknown | Phase 1 / Phase 2 | 90 | Takayuki YoshinoOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT05035914 | Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer | unknown | Phase 1 / Phase 2 | 94 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03126071 | Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | unknown | Phase 2 | 100 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Aug 30, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 26, 2022source: clinicaltrials